TL;DR: CJC-1295 and ipamorelin are frequently framed as rivals, but they are not really alternatives — they act on two different receptors and are among the most commonly co-studied peptides precisely because their mechanisms complement each other. CJC-1295 is a GHRH analog that raises the growth hormone baseline; ipamorelin is a ghrelin-receptor agonist that sharpens the pulse. This guide explains the real difference and when each is studied alone.
Search interest often pits CJC-1295 against ipamorelin as an either/or choice. The more useful framing is mechanistic: they occupy different halves of the growth hormone (GH) control system. Understanding that is the key to reading any protocol that uses one, the other, or both.
Two Different Receptors
Growth hormone release is governed by two complementary inputs, and these two peptides each act on one of them:
- CJC-1295 is a GHRH analog — it mimics growth-hormone-releasing hormone and acts on the GHRH receptor, driving GH synthesis and raising the secretory baseline.
- Ipamorelin is a growth hormone secretagogue — it acts on the ghrelin receptor (GHS-R1a) to amplify and sharpen the GH pulse.
Because they act on separate receptors, they are additive rather than redundant. This is the entire reason they are so often studied as a pair rather than as competitors.
- 1
CJC-1295 (GHRH)
Raises the baseline drive for growth hormone synthesis and release.
- 2
Ipamorelin (GHS-R)
Amplifies the pulse on top of that raised baseline.
- 3
Combined
Research reports a synergistic GH response greater than either produces alone.
Head-to-Head Comparison
| Feature | CJC-1295 | Ipamorelin |
|---|---|---|
| Class | GHRH analog | GH secretagogue (GHRP) |
| Receptor | GHRH receptor | Ghrelin receptor (GHS-R1a) |
| Effect on GH | Raises baseline | Amplifies the pulse |
| Selectivity | GHRH-specific | Clean — minimal cortisol/prolactin |
| Half-life | ~30 min (no DAC) to ~8 days (with DAC) | ~2 hours |
| Dosing rhythm | Varies by DAC status | 2-3x daily |
Qualitative illustration from the research literature, not a potency ranking.
The CJC-1295 DAC Wrinkle
One reason CJC-1295 is harder to compare directly is that it exists in two forms, which behave very differently:
- CJC-1295 without DAC (Mod GRF 1-29) — short half-life (~30 minutes), pulsatile, dosed 2-3x daily. This is the form that pairs most naturally with ipamorelin’s rhythm.
- CJC-1295 with DAC — the Drug Affinity Complex extends the half-life to around 8 days, producing a sustained baseline elevation rather than discrete pulses.
For the full distinction, see CJC-1295 DAC vs no DAC. The no-DAC form is the usual partner in pulse-preserving research because its short half-life keeps the GH signal pulsatile — closer to the body’s own rhythm.
When Each is Studied Alone
Despite the pairing logic, there are research contexts for each on its own:
- CJC-1295 alone — when the question is specifically about GHRH-pathway drive, or when a sustained baseline (DAC form) is the variable of interest.
- Ipamorelin alone — when a clean, selective GH pulse is needed without off-target cortisol or prolactin effects; ipamorelin’s selectivity is its defining advantage, covered in our what is ipamorelin overview.
For research that wants both mechanisms together, a pre-blended CJC-1295 + Ipamorelin blend (5mg) co-delivers them, and our common peptide stacks guide places the pairing in context.
Reconstitution & Handling
Both are supplied as lyophilised powders reconstituted with bacteriostatic water. Ipamorelin vials come in 2mg, 5mg, and 10mg; CJC-1295 (no DAC) in 2mg and 5mg. To model any vial and dose, use the reconstitution calculator, and for procedure see the peptide reconstitution guide.
Safety, Legality & Research Disclaimers
Both CJC-1295 and ipamorelin are research peptides. Neither is an approved medicine, and neither has been authorised for therapeutic use in humans. They should be treated strictly as laboratory research chemicals, handled by qualified individuals, and used only for legitimate research purposes. Regulatory status varies by jurisdiction, and researchers are responsible for confirming compliance with applicable local laws and institutional requirements. Nothing here is medical advice.
FAQ
Is CJC-1295 or ipamorelin better?
Neither is strictly “better” — they do different jobs. CJC-1295 is a GHRH analog that raises the growth hormone baseline; ipamorelin is a ghrelin-receptor agonist that amplifies the pulse. They act on different receptors, which is why research so often studies them together rather than choosing between them.
Why are CJC-1295 and ipamorelin used together?
Because their mechanisms are complementary. CJC-1295 increases the underlying drive for GH release, and ipamorelin sharpens and amplifies the resulting pulse. The research literature reports a combined GH response greater than either compound produces on its own.
Does the DAC version change the comparison?
Yes. CJC-1295 without DAC has a short (~30 minute) half-life and is dosed several times a day, pairing naturally with ipamorelin. CJC-1295 with DAC has a ~8-day half-life and produces a sustained baseline rather than pulses, which is a different research question entirely.
Which one is more selective?
Ipamorelin. It produces a clean GH pulse with minimal effect on cortisol and prolactin, whereas CJC-1295 works through the separate GHRH pathway. Selectivity is ipamorelin’s defining characteristic within the secretagogue class.
References
- Raun K, et al. “Ipamorelin, the first selective growth hormone secretagogue.” European Journal of Endocrinology. 1998.
- Teichman SL, et al. “Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295.” J Clin Endocrinol Metab. 2006.
- Research literature on GHRH analog and secretagogue co-administration for synergistic growth hormone release.
Last updated: July 12, 2026
Disclaimer: This information is for educational and research purposes only. Peptides are research chemicals not intended for human consumption. See the CJC-1295 and Ipamorelin research pages for reconstitution detail.